Latest News On FDA

Latest California Healthline Stories

KFF Health News' 'What the Health?': Waiting for SCOTUS

June is when the Supreme Court typically issues rulings in the major cases it hears during that year’s term. This year, those interested in health policy are awaiting decisions in two abortion-related cases and one that could reshuffle the way health policies (and all other federal policies) are made. In this special episode, KFF’s Laurie Sobel, associate director for women’s health policy, joins Julie Rovner for a review of the cases and a preview of how the court might rule.

Psychoactive Drugs Are Having a Moment. The FDA Will Soon Weigh In.

Mounting evidence suggests psychoactive drugs including LSD, ketamine, mushrooms, and MDMA can be powerful treatments for severe depression and PTSD. But not everyone is convinced. And even if such drugs gain FDA approval, safety protocols could render them extremely expensive.

FDA Said It Never Inspected Dental Lab That Made Controversial AGGA Device

Johns Dental Laboratories stopped making the Anterior Growth Guidance Appliance last year after a KFF Health News-CBS News investigation into allegations of patient harm. The company had “never” reported any complaints about its products to the FDA, according to the agency.

Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge

The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.

What’s Keeping the US From Allowing Better Sunscreens?

A decade after Congress told the FDA to expedite the approval of more effective sunscreens, the federal government still has not approved sunscreen ingredients that are safely being used around the world. Meanwhile, skin cancer is the nation’s most common cancer.

KFF Health News' 'What the Health?': Abortion Access Changing Again in Florida and Arizona

A six-week abortion ban took effect in Florida this week, dramatically restricting access to the procedure not just in the nation’s third-most-populous state but across the South. Patients from states with even more restrictive bans had been flooding in since the overturn of Roe v. Wade in 2022. Meanwhile, the CEO of the health behemoth UnitedHealth Group appeared before committees in both the House and Senate, where lawmakers grilled him about the February cyberattack on subsidiary Change Healthcare and how its ramifications are being felt months later. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachana Pradhan of KFF Health News join KFF Health News’ Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.